865156-48-5 Usage
Description
7-Bromoimidazo[1,5-a]pyridine is a chemical compound belonging to the imidazopyridine class, characterized by the presence of a bromine atom at the 7th position and a pyridine ring fused to an imidazole ring. This structural feature endows it with unique chemical and biological properties, making it a valuable molecule for various applications in the pharmaceutical and chemical industries.
Uses
Used in Pharmaceutical Research:
7-Bromoimidazo[1,5-a]pyridine is used as a key intermediate in the synthesis of novel imidazopyridine GSK-3β inhibitors. These inhibitors are of significant interest due to their potential role in the treatment of various diseases, including neurodegenerative disorders and cancer, by targeting the glycogen synthase kinase-3β (GSK-3β) enzyme.
Used in Computational Chemistry:
7-Bromoimidazo[1,5-a]pyridine is employed in computational approaches to support the discovery and optimization of imidazopyridine GSK-3β inhibitors. By using computational methods, researchers can predict the binding affinity, selectivity, and potential off-target effects of these inhibitors, thereby accelerating the drug discovery process and improving the chances of identifying effective and safe therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 865156-48-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,5,1,5 and 6 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 865156-48:
(8*8)+(7*6)+(6*5)+(5*1)+(4*5)+(3*6)+(2*4)+(1*8)=195
195 % 10 = 5
So 865156-48-5 is a valid CAS Registry Number.
865156-48-5Relevant articles and documents
HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF
-
, (2015/07/07)
Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.
